Comparison · NCT02587936-127b1fb1
Intervention vs Usual Care: 30-day All Cause Readmissions (for Those Patients Who Have an Index Hospitalization)
Calculated by ConductScience from the counts the trial posted to ClinicalTrials.gov.
2 sourcestrial-comparisons-2026-03-23-0.1.0
Cite this record
ConductScience Library. Intervention vs Usual Care: 30-day All Cause Readmissions (for Those Patients Who Have an Index Hospitalization). Trial comparisons, record NCT02587936-127b1fb1. Release trial-comparisons-2026-03-23-0.1.0, 23 Mar 2026. https://conductscience.org/library/comparisons/NCT02587936-127b1fb1
On this page
Measures6
Calculated by ConductScience from the counts the trial posted to ClinicalTrials.gov.
| Measure | Value | 95% interval, lower | 95% interval, upper | Method | Note |
|---|---|---|---|---|---|
| Risk in group 1 | 0.377 | 0.349 | 0.405 | wilson | |
| Risk in group 2 | 0.373 | 0.346 | 0.401 | wilson | |
| Risk difference, group 1 minus group 2 | 0.00337 | -0.0362 | 0.0429 | newcombe hybrid score | |
| Risk ratio, group 1 over group 2 | 1.01 | 0.908 | 1.12 | log | |
| Odds ratio, group 1 over group 2 | 1.01 | 0.857 | 1.2 | log | |
| Number needed to treat, for one more participant with the outcome on Intervention than on Usual Care | 297 | from the risk difference interval | the interval includes no difference |
Source ClinicalTrials.gov
Groups2
Group 2 names the comparator: usual care.
| Group | Title | Description | With the outcome | Analysed | ClinicalTrials.gov code |
|---|---|---|---|---|---|
| Group 1 | Intervention | Group to receive Collaborative model of primary care and subspecialty care enhanced by Pieces and Practice Facilitator~Collaborative Model of Primary care and Subspecialty care: Pieces will access Electronic Health Record for all patients receiving care at the participating sites to detect patients with a triad of chronic kidney disease, diabetes and hypertension, facilitate management and monitor outcomes. To maximize successful implementation of care, a Practice Facilitator will be at each site with standardized role training using a curriculum based on the Agency for Healthcare Research and Quality (AHRQ) Practice Facilitation Handbook. Specific interventions are maintaining BP less than 140/90 mmHg, use of angiotensin-converting-enzyme inhibitor (ACEI) or angiotensin receptor blocker (ARB), treatment with statins, aiming for glycosylated Hemoglobin (HgA1C) at the recommended target, and avoiding nephrotoxic medications. Additional interventions include chronic kidney disease education for Primary Care Providers (PCP) and patients using National Kidney Disease Education Program (NKDEP) materials. | 429 | 1,139 | OG000 |
| Group 2 | Usual Care | Group to receive usual care | 433 | 1,160 | OG001 |
Source ClinicalTrials.gov
Outcome
- Type
- SECONDARY
- Title
- 30-day All Cause Readmissions (for Those Patients Who Have an Index Hospitalization)
- Description
30-day all-cause readmissions (for those patients who have an index hospitalization), emergency room visits, cardiovascular events and deaths, and disease-specific hospitalizations for cardiovascular complications, congestive heart failure, volume overload, hypertension complications, acute coronary syndrome, myocardial infarction, coronary/peripheral revascularization, stroke, amputation/limb ischemia, uncontrolled diabetes, hypoglycemia, diabetes complications, acute kidney injury, hyperkalemia, electrolyte disturbances, medication errors, drug toxicity, and infections.
- Time frame
- 12 months
- Population
Source ClinicalTrials.gov
Trial
- Title
- Improving Chronic Disease Management With Pieces
- NCT number
- NCT02587936
- Phases
- NA
- Conditions
- Chronic Kidney Disease, Diabetes, Hypertension, High BP, Type 2 Diabetes
- Interventions
- Collaborative Model of Primary care and Subspecialty care
- Lead sponsor
- University of Texas Southwestern Medical Center
- Results first posted
- 2023-12-20
- Results on ClinicalTrials.gov
- https://clinicaltrials.gov/study/NCT02587936?tab=results
Source ClinicalTrials.gov
Source
- Release
- trial-comparisons-2026-03-23-0.1.0
- Release manifest SHA-256
- f66225897fbf258b57ea10bdacfd0347d3cdfda93f7f5685234b7e06ea36fa57
- AACT copy
- 2026-03-23
- Tables read
- outcome_counts.parquet, outcome_measurements.parquet, outcomes.parquet, reported_event_totals.parquet, reported_events.parquet, result_groups.parquet, studies.parquet, ctgov_trial.parquet
Source ClinicalTrials.gov
Sources 2
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions. The measures are ConductScience's calculation from them.
For software
Read this comparison from software.
The record is JSON. No key.
GET https://conductscience.org/api/comparisons/v1/NCT02587936-127b1fb1